Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention

Fig. 2

CYP2C19*2, CYP2C19 *3, PON-1Q192R genotypes and ADP- induced platelet aggregation inhibition rates. a: CYP2C19*2 and ADP induced platelet aggregation inhibition rates; b: CYP2C19*3 and ADP induced platelet aggregation inhibition rates; c: PONQ192R and ADP induced platelet ggregation inhibition rates; d: CYP2C19*2 or *3 genotypes and ADP- induced platelet inhibition rates; p-value< 0.05: ADP induced platelet aggregation inhibition rates is significant difference between different genotype

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us